04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
20:09 , Oct 5, 2018 |  BC Week In Review  |  Company News

Roche developing cancer antibody on Go’s glycotargeting platform

Go Therapeutics Inc. (Cambridge, Mass.) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to develop and commercialize a glycotargeting bispecific antibody developed using Go Therapeutics’s platform for $9 million in an upfront payment and near-term milestones....
16:43 , Sep 21, 2018 |  BC Week In Review  |  Company News

Atomwise identifying small molecules for Pfizer

Atomwise Inc. (San Francisco, Calif.) partnered with Pfizer Inc. (NYSE:PFE) to use its AI platform to identify small molecule candidates for up to three target proteins from Pfizer. Atomwise will receive an undisclosed technology access...
21:13 , Sep 12, 2018 |  BC Extra  |  Preclinical News

Genentech develops antibiotic against multidrug resistant Gram-negatives

Genentech Inc. researchers have developed arylomycin derivatives with potent activity against Gram-negative bacteria, including multidrug resistant (MDR) strains. The small molecule could represent a notable step forward against Gram-negative bacteria, for which no new class...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
19:48 , Aug 23, 2018 |  BC Extra  |  Tools & Techniques

Computational tool prospectively predicts resistance to cancer drugs

An Institute of Cancer Research team has developed a computational prediction tool that can predict which resistant mutations will develop in response to cancer drugs before a patient takes the drug. The results suggest the...
22:49 , Aug 10, 2018 |  BC Extra  |  Preclinical News

New approach could identify Ras-blocking small molecules

With an eye on historically undruggable cancer target Ras, a University of Oxford team and colleagues devised a way to find small molecules that have the same qualities as Ras inhibitors too large to access...
06:14 , Aug 10, 2018 |  BC Week In Review  |  Company News

Regeneron, bluebird ink multitarget deal for cancer

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
22:43 , Aug 6, 2018 |  BC Extra  |  Company News

Regeneron, bluebird in multitarget cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
19:29 , Aug 1, 2018 |  BC Innovations  |  Emerging Company Profile

Connecting the DotBodies

Cancer play DotBio Pte. Ltd. launched this week with a screening platform to discover and develop products based on humanized domain antibodies that could be more stable and easier to manufacture than other domain antibodies....